- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00117507
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-Risk and INT-1 Myelodysplastic Patients
Thirty patients were to be enrolled and 24 patients were actually enrolled into this open-label, single-arm trial designed to assess the safety and tolerability of oral deferasirox in adult transfusion dependent myelodysplastic syndrome (MDS) patients with iron overload. Patients enrolled in this study had low or intermediate (INT-1) risk MDS per International Prognostic Scoring System (IPSS) criteria. All patients initiated treatment with 20mg/kg/day deferasirox.
Deferasirox were administered orally once per day for 12 months.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305-5821
- Stanford University Medical Center
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Center
-
-
Texas
-
Houston, Texas, United States, 77030-4009
- MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients with low or intermediate (INT-1) risk MDS, determined via IPSS criteria, with transfusional iron overload. NOTE: Bone marrow morphology and cytogenetic studies completed within 3 months prior to screening can be used if the patient has been hematologically stable. Every attempt to obtain cytogenetics studies should be made; however, if there is culture failure, repeat marrow aspiration will not be mandated. In this case, RAEB with less than 11% marrow blasts will be accepted.
- Patients on chelation therapy at the time of screening required a 1-day wash out prior to the first dose of study drug.
- Age: greater than or equal to 18 years
Serum ferritin:
- For entry into the screening period: serum ferritin greater than or equal to 1000 µg/mL on at least two occasions, at least two weeks apart, during the prior year. Samples must be obtained in the absence of concomitant infection;
- For enrollment into the study: serum ferritin greater than or equal to 1000 µg/mL at screening (via the central lab) obtained in the absence of concomitant infection
- A lifetime minimum of 20 previous packed red cell transfusions
- Life expectancy greater than or equal to 6 months
- Women must have a negative serum or urine pregnancy test and use an effective method of contraception, or must have undergone clinically documented total hysterectomy and/or oophorectomy, or tubal ligation or be postmenopausal (defined by amenorrhea for at least 12 months).
- Able to provide written informed consent
Exclusion Criteria:
- Serum creatinine greater than 2 × upper limit of normal (ULN)
- ALT or AST greater than 5 × ULN.
- Clinical or laboratory evidence of active hepatitis B or hepatitis C (HBsAg in the absence of HBsAb -OR- HCV Ab positive with HCV RNA positive and ALT above the normal range)
- Significant proteinuria as indicated by a urinary protein/creatinine ratio greater than 0.5 mg/mg in a non-first void urine sample during screening (or alternatively in two of three samples obtained for screening)
- History of HIV positive test result (ELISA or Western blot)
- ECOG performance status greater than 2
- Uncontrolled systemic hypertension
- Unstable cardiac disease not controlled by standard medical therapy
- Third degree atrioventricular (AV) block or QT interval prolongation above the normal range
- History of clinically relevant ocular toxicity related to iron chelation
- Pregnancy or breast feeding
- Treatment with a systemic investigational drug within the past 4 weeks or a topical investigational drug within the past 7 days.
Other surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug. The investigator should be guided by evidence of any of the following:
- inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or rectal bleeding;
- major gastrointestinal tract surgery, such as gastrectomy, gastroenterostomy, or bowel resection;
- pancreatic injury or pancreatitis or indications of impaired pancreatic function/injury, as indicated by abnormal lipase or amylase;
- urinary obstruction or difficulty in voiding.
- History of non-compliance to medical regimens or patients who are considered potentially unreliable and/or not cooperative
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Deferasirox
Participants received deferasirox 20mg/kg/day OD for 12 months.
Deferasirox was taken every morning 30 minutes before breakfast, if possible consistently around the same time between 7:00 and 9:00 AM.
The tablets was dropped into water or orange juice and gently stirred for 1 to 3 minutes until completely dispersed.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events and Serious Adverse Events
Time Frame: Up To Week 52
|
An adverse event (AE) is any untoward medical occurrence (e.g.
any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or clinical investigation subject after providing written informed consent for participation in the study.
Any sign or symptom that occured from first dose of study treatment until end of study treatment.
|
Up To Week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute Change in Serum Ferritin From Baseline to Week 52
Time Frame: Baseline to Week 52
|
Absolute change in serum ferritin after start of treatment with Deferasirox (ICL670).
|
Baseline to Week 52
|
Absolute Change in Liver Iron Concentration (LIC) From Baseline to End of Study
Time Frame: Baseline to Week 52
|
LIC was assessed using magnetic resonance imaging (MRI) mean liver proton transverse relaxation rates (R2).
|
Baseline to Week 52
|
To Evaluate Change in Transfusion Requirements
Time Frame: Baseline to Week 52
|
Change in transfusion requirements from baseline.
|
Baseline to Week 52
|
Absolute Change in Serum Erythropoietin
Time Frame: Baseline to Week 52
|
Absolute Change in Serum Erythropoietin from baseline.
|
Baseline to Week 52
|
Absolute Change in Urinary Hepcidin
Time Frame: Baseline to Week 52
|
Absolute Change in Urinary Hepcidin from baseline
|
Baseline to Week 52
|
Absolute Change in Transferrin Saturation
Time Frame: Baseline to Week 52
|
Transferrin Saturation was assessed using magnetic resonance imaging (MRI) mean liver proton transverse relaxation rates (R2)
|
Baseline to Week 52
|
Labile Plasma Iron (LPI)
Time Frame: Baseline to Week 52
|
LPI represents the component of non-transferrin bound iron and is an indicator of iron overload.
The outcome was reported as LPI Unit, where, 1 LPI unit = the quantity of reactive oxygen species produced by approximately 1.5 μM Fe.
|
Baseline to Week 52
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Neoplasms
- Disease
- Bone Marrow Diseases
- Hematologic Diseases
- Iron Metabolism Disorders
- Precancerous Conditions
- Syndrome
- Myelodysplastic Syndromes
- Iron Overload
- Preleukemia
- Molecular Mechanisms of Pharmacological Action
- Sequestering Agents
- Iron Chelating Agents
- Deferasirox
- Chelating Agents
Other Study ID Numbers
- CICL670AUS02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndromes
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
National Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
GCP-Service International West GmbHSaint-Louis Hospital, Paris, France; University of Florence; Medical University... and other collaboratorsNot yet recruitingLow Risk Myelodysplastic SyndromesSpain, Poland, Italy, Germany, France
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes (MDS)United States
-
TJ Biopharma Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
-
Sumitomo Pharma America, Inc.TerminatedMyelodysplastic Syndromes (MDS)United States
Clinical Trials on Deferasirox
-
Novartis PharmaceuticalsCompletedTransfusion-dependent AnemiaEgypt, Hungary, Turkey, United States, Bulgaria, Italy, Belgium, Russian Federation, Philippines, France, Malaysia, India, Oman, Panama, Lebanon, Thailand, Tunisia
-
Novartis PharmaceuticalsCompletedNon-transfusion-dependent Thalassemia | Transfusion-dependent ThalassemiaEgypt, Turkey, Thailand, Lebanon, Morocco, Saudi Arabia, Vietnam
-
DisperSol Technologies, LLCCompletedThalassemia MajorThailand, United States
-
Novartis PharmaceuticalsWithdrawnThalassemia (Transfusion Delendent)
-
Assistance Publique - Hôpitaux de ParisAssociation pour l'Etude des Fonctions Digestives (AEFD)UnknownPorphyria Cutanea TardaFrance
-
Novartis PharmaceuticalsCompletedLow and Int 1-risk Myelodysplastic SyndromeGermany, Canada, Korea, Republic of, Sweden, Spain, China, Argentina, Italy, United Kingdom, Algeria
-
NovartisCompletedBeta-Thalassemia | HemosiderosisEgypt, Lebanon, Oman, Saudi Arabia, Syrian Arab Republic
-
Novartis PharmaceuticalsCompletedNon-transfusion Dependent ThalassemiaThailand, Turkey, Italy, Greece, China, United Kingdom, Lebanon, Tunisia
-
City of Hope Medical CenterTerminatedPrimary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Iron Overload | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell... and other conditionsUnited States
-
Crolll GmbhUniversity of Magdeburg; Estimate, GmbHCompletedNon-alcoholic Steatohepatitis | Increased Iron Storage / Disturbed DistributionGermany